Technical Analysis for APGE - Apogee Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Volume Surge | Other | -1.96% | |
| Multiple of Ten Bearish | Other | -1.96% | |
| MACD Bullish Signal Line Cross | Bullish | -3.43% | |
| Multiple of Ten Bearish | Other | -3.43% | |
| Oversold Stochastic | Weakness | 0.86% | |
| Wide Bands | Range Expansion | 2.96% | |
| Oversold Stochastic | Weakness | 2.96% |
| Alert | Time |
|---|---|
| Down 1% | about 6 hours ago |
| Possible NR7 | about 6 hours ago |
| Possible Inside Day | about 6 hours ago |
| Up 2% | about 10 hours ago |
| Up 1% | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 72.29 |
| 52 Week Low | 14.22 |
| Average Volume | 452,422 |
| 200-Day Moving Average | 36.39 |
| 50-Day Moving Average | 46.31 |
| 20-Day Moving Average | 40.86 |
| 10-Day Moving Average | 38.40 |
| Average True Range | 2.50 |
| RSI (14) | 39.02 |
| ADX | 24.7 |
| +DI | 19.78 |
| -DI | 23.74 |
| Chandelier Exit (Long, 3 ATRs) | 39.92 |
| Chandelier Exit (Short, 3 ATRs) | 43.77 |
| Upper Bollinger Bands | 46.31 |
| Lower Bollinger Band | 35.42 |
| Percent B (%b) | 0.29 |
| BandWidth | 26.66 |
| MACD Line | -2.50 |
| MACD Signal Line | -2.71 |
| MACD Histogram | 0.2108 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 41.01 | ||||
| Resistance 3 (R3) | 41.28 | 40.74 | 40.61 | ||
| Resistance 2 (R2) | 40.74 | 40.12 | 40.61 | 40.47 | |
| Resistance 1 (R1) | 39.66 | 39.74 | 39.39 | 39.39 | 40.33 |
| Pivot Point | 39.12 | 39.12 | 38.99 | 38.99 | 39.12 |
| Support 1 (S1) | 38.04 | 38.50 | 37.77 | 37.77 | 36.83 |
| Support 2 (S2) | 37.50 | 38.12 | 37.37 | 36.69 | |
| Support 3 (S3) | 36.42 | 37.50 | 36.56 | ||
| Support 4 (S4) | 36.15 |
